Flavagline derivatives
US10047064B2 · kind B2 · utility
1Cited by
2References
12Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 6, 2015 |
| Grant date | Aug 14, 2018 |
| Priority date | — |
| Expiry date | Jul 6, 2035 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D498/04
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
The invention relates to compounds of the following general formula (I) in the form of one of the enantiomers thereof or a mixture of the enantiomers thereof, and the pharmaceutically acceptable salts and/or solvates thereof, especially for the use thereof as a medicament, more specifically in cancer treatment. The invention also relates to pharmaceutical compositions containing same and to the methods for the production thereof.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.